Repare Therapeutics (RPTX)
(Delayed Data from NSDQ)
$1.52 USD
-0.01 (-0.65%)
Updated Aug 7, 2025 04:00 PM ET
After-Market: $1.54 +0.02 (1.32%) 5:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RPTX 1.52 -0.01(-0.65%)
Will RPTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RPTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RPTX
CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates
What Makes Repare Therapeutics (RPTX) a New Buy Stock
RPTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Myriad Genetics (MYGN) Meets Q4 Earnings Estimates
Repare Therapeutics (RPTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Repare Therapeutics (RPTX) Loses -5.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for RPTX
Repare Therapeutics Jumps 15% After $10M Licensing Deal With Debiopharm
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket
Closing Bell Movers: Victory Capital gains on S&P 400 inclusion
12 Health Care Stocks Moving In Tuesday's After-Market Session